London Genetics Expands its Senior Advisory Team

LONDON, July 22, 2010 - London Genetics Limited, an expert in the use of pharmacogenetics in
clinical drug discovery and development, is pleased to announce that it
has augmented the strength of its team with the appointment of two senior
advisers, Professors Stephen DeCherney and Munir Pirmohamed. With their
extensive clinical, healthcare, and drug development expertise, their
guidance will be invaluable to London Genetics.

Stephen DeCherney MD, MPH, is Professor of Medicine at the University of
Carolina, and was previously President, Global Clinical Organisation and
Chief Innovation Officer at Quintiles Transnational Corporation. With
research interests in internal medicine, endocrinology and diabetes,
Professor DeCherney spent five years at the US National Institutes of
Health, followed by various management roles at the Christiana Care Health
System in Delaware, where he was principal investigator in more than 100
clinical trials. He is on the Board of Certara, Inc and has an MPH from
Columbia University School of Public Health.

As holder of the NHS Chair of Pharmacogenetics at the University of
Liverpool, Professor Munir Pirmohamed MB, ChB (Hons), PhD, FRCP, FRCP(E)
is a leading researcher in the area of pharmacogenetics and drug safety.
He is involved in the European EU-PACT Phase IV study, which is looking at
the effect of gene-based dosing of warfarin on 2000 patients, and is
expected to provide an important indication of the value pharmacogenetics
can bring to clinical practice. After qualifying in medicine, Professor
Pirmohamed obtained a PhD in pharmacology, and is Deputy Director of the
MRC Centre for Drug Safety Sciences in Liverpool and Director of the
Wolfson Centre for Personalised Medicine.

Commenting on these appointments, Dominique Kleyn, CEO of London
Genetics, said 'Steve and Munir bring fantastic expertise to the London
Genetics team, and we are delighted that they have joined us. As we continue
partnering discussions with a range of stakeholders, their input and
advice is invaluable. We look forward to sharing this insight with
delegates at our second pharmacogenetics conference, to be held in
November 2010 in Windsor, UK1.'

1 2nd Annual London Genetics Pharmacogenetics Conference ,
"Pharmacogenetics: Why, How and When? Challenges, Opportunities and How to
Harness the Value", 9th - 10th November 2010, Cumberland Lodge, Winsdor, UK.

For more information, go to
www.londongenetics.com/london-genetics-events/basic

Notes to Editors:

About London Genetics

London Genetics Limited, a not-for-profit company, is an expert in the
use of pharmacogenetics in clinical drug discovery and development.
Established in 2007 with funding from the London Development Agency, its
seven founding partners are leading London academic and medical institutions
with clinical and genetic expertise and significant patient resources. The
company provides pharmaceutical and biotechnology companies with access to
this expertise and resource, as well as providing strategic advice on the
application of pharmacogenetics for successful drug development. LGL has
broad therapeutic expertise with a focus on cardiovascular disease and
drug side-effects of a cardiovascular nature. Recent agreements developed
by London Genetics include a collaboration between the International
Serious Adverse Events Consortium, St George's University of London and
the Drug Safety Research Unit at Southampton, UK. The parties are working
on genetic markers for drug-induced cardiac arrhythmia. LGL is based in
central London and has ISO 9001 accreditation. For further information,
please go to www.londongenetics.com

About pharmacogenetics

Genetic differences between individuals mean that drug response rates
are often variable across a population, and this has significant implications
for healthcare cost effectiveness. Pharmocogenetics, the study of the
clinical consequences of genetic differences in the way
people metabolise and respond to drugs, is expected to generate better
understanding of how drugs work in the body, and therefore give insight
into how to develop more efficacious and safer drugs. It also
has implications for product life cycle management and the revitalisation
of drugs which previously failed in clinical trials. With drug development
costs rising and R&D productivity falling, plus increased regulator focus
on safety and cost-effectiveness, pharmacogenetics is expected to become
increasingly important in drug development. The FDA and the EMA have
recognised this in their Critical Path Initiative and Road Map respectively.

    Pictures available on request.

    For further information please contact:

    London Genetics Ltd

    Dominique Kleyn
    CEO
    +44(0)207-594-1838

    Emma Palmer Foster
    Strategic Communications Consultant
    +44(0)7880-787-185

    communications@londongenetics.com

For further information please contact: London Genetics Ltd, Dominique Kleyn, CEO, +44(0)207-594-1838; Emma Palmer Foster, Strategic Communications Consultant , +44(0)7880-787-185; communications at londongenetics.com